Covax Pharmaceutical: Planning to list on the Hong Kong Stock Exchange.

Kexing Pharmaceuticals announced that the company is planning to issue shares for overseas listing and to list them on the Hong Kong Stock Exchange. This move aims to deepen the "innovation + internationalization" strategy, accelerate overseas business development, enhance overall competitiveness and international brand image, optimize capital structure, and diversify financing channels. The details are yet to be confirmed, and require approval from the company's board of directors and shareholders, as well as filing, approval, or authorization from relevant government and regulatory agencies. There is uncertainty as to whether the H-share listing can pass through the review, filing, and approval processes and ultimately be implemented.